More recently, trastuzumab was shown to be effective as adjuvant treatment in breast-carcinoma patients with ERBB2 amplification/overexpression (Piccart-Gebhart et al, 2005; Romond et al, 2005). This evidence concerns the gene ERBB2 and breast carcinoma.